Remittive Effects of Intramuscular Alefacept in Psoriasis

December 2003 | Volume 2 | Issue 6 | Original Article | 624 | Copyright © 2003

Kenneth B. Gordon, MD and Richard Langley, MD


Alefacept is the first biologic agent approved for the treatment of chronic plaque psoriasis in the United States. Alefacept, administered intravenously (IV) or intramuscularly (IM), was found to be well tolerated, safe, and efficacious in two pivotal phase 3 studies in patients with moderate to severe psoriasis. Treatment with IV alefacept was associated with a median duration of off-treatment response of 216 days (approximately 7 months). In a follow-up extension study to the phase 3 IM study, duration of therapeutic response was also examined. Patients who achieved a ?75% reduction in baseline Psoriasis Area and Severity Index (PASI 75) with the first course of alefacept 15 mg IM in the phase 3 study maintained a PASI 50 for a median duration of 209 days. In addition, the extension study demonstrated that a second course of IM alefacept is safe and well tolerated in patients with psoriasis.

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

Related Articles